News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
311,563 Results
Type
Article (14339)
Company Profile (109)
Press Release (297115)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (99379)
Career Advice (570)
Deals (20509)
Drug Delivery (67)
Drug Development (39976)
Employer Resources (49)
FDA (7005)
Job Trends (7178)
News (171184)
Policy (15548)
Tag
Academia (506)
Accelerated approval (2)
Adcomms (6)
Allergies (39)
Alliances (26480)
ALS (47)
Alzheimer's disease (488)
Antibody-drug conjugate (ADC) (49)
Approvals (7051)
Artificial intelligence (119)
Autoimmune disease (9)
Automation (4)
Bankruptcy (189)
Best Places to Work (5269)
BIOSECURE Act (9)
Biosimilars (59)
Biotechnology (46)
Bladder cancer (26)
Brain cancer (16)
Breast cancer (98)
Cancer (802)
Cardiovascular disease (78)
Career advice (501)
Career pathing (12)
CAR-T (26)
Cell therapy (110)
Cervical cancer (4)
Clinical research (33775)
Collaboration (395)
Compensation (187)
Complete response letters (17)
COVID-19 (814)
CRISPR (23)
C-suite (136)
Cystic fibrosis (45)
Data (859)
Denatured (15)
Depression (13)
Diabetes (101)
Diagnostics (1908)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (64)
Drug pricing (70)
Drug shortages (12)
Duchenne muscular dystrophy (39)
Earnings (36639)
Editorial (14)
Employer branding (4)
Employer resources (43)
Events (44392)
Executive appointments (444)
FDA (7571)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (279)
Gene editing (43)
Generative AI (9)
Gene therapy (108)
GLP-1 (364)
Government (1425)
Grass and pollen (3)
Guidances (67)
Healthcare (5077)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (39)
Indications (15)
Infectious disease (858)
Inflammatory bowel disease (70)
Inflation Reduction Act (6)
Influenza (19)
Intellectual property (55)
Interviews (77)
IPO (9213)
IRA (29)
Job creations (2151)
Job search strategy (448)
Kidney cancer (6)
Labor market (14)
Layoffs (184)
Leadership (4)
Legal (3953)
Liver cancer (19)
Lung cancer (114)
Lymphoma (63)
Machine learning (4)
Management (16)
Manufacturing (184)
MASH (37)
Medical device (2943)
Medtech (2945)
Mergers & acquisitions (11702)
Metabolic disorders (292)
Multiple sclerosis (25)
NASH (14)
Neurodegenerative disease (25)
Neuropsychiatric disorders (8)
Neuroscience (709)
NextGen: Class of 2025 (2220)
Non-profit (725)
Now hiring (8)
Obesity (158)
Opinion (121)
Ovarian cancer (28)
Pain (66)
Pancreatic cancer (34)
Parkinson's disease (59)
Partnered (10)
Patents (146)
Patient recruitment (38)
Peanut (11)
People (31938)
Pharmaceutical (64)
Pharmacy benefit managers (13)
Phase I (9089)
Phase II (14524)
Phase III (12465)
Pipeline (622)
Policy (75)
Postmarket research (1427)
Preclinical (3667)
Press Release (26)
Prostate cancer (52)
Psychedelics (8)
Radiopharmaceuticals (138)
Rare diseases (186)
Real estate (2947)
Recruiting (17)
Regulatory (11123)
Reports (16)
Research institute (653)
Resumes & cover letters (67)
Rett syndrome (1)
RNA editing (2)
RSV (11)
Schizophrenia (42)
Series A (45)
Series B (21)
Service/supplier (3)
Sickle cell disease (37)
Special edition (6)
Spinal muscular atrophy (78)
Sponsored (6)
Startups (1887)
State (2)
Stomach cancer (4)
Supply chain (34)
Tariffs (37)
The Weekly (30)
Vaccines (177)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Last 7 days (394)
Last 30 days (1210)
Last 365 days (14037)
2025 (5056)
2024 (15349)
2023 (17676)
2022 (23558)
2021 (24856)
2020 (23765)
2019 (18185)
2018 (14264)
2017 (16086)
2016 (14953)
2015 (18006)
2014 (14142)
2013 (11993)
2012 (12940)
2011 (13195)
2010 (12114)
Location
Africa (317)
Alabama (15)
Alaska (1)
Arizona (79)
Arkansas (3)
Asia (22163)
Australia (2896)
California (2381)
Canada (1047)
China (281)
Colorado (85)
Connecticut (106)
Delaware (72)
Europe (42198)
Florida (449)
Georgia (56)
Idaho (14)
Illinois (236)
India (16)
Indiana (157)
Iowa (1)
Japan (107)
Kansas (65)
Kentucky (14)
Louisiana (2)
Maine (37)
Maryland (336)
Massachusetts (1911)
Michigan (92)
Minnesota (122)
Mississippi (2)
Missouri (26)
Montana (10)
Nebraska (8)
Nevada (35)
New Hampshire (12)
New Jersey (955)
New Mexico (8)
New York (752)
North Carolina (552)
North Dakota (2)
Northern California (958)
Ohio (67)
Oklahoma (4)
Oregon (18)
Pennsylvania (598)
Puerto Rico (8)
Rhode Island (13)
South America (535)
South Carolina (8)
Southern California (1001)
Tennessee (45)
Texas (359)
United States (9810)
Utah (72)
Virginia (86)
Washington D.C. (32)
Washington State (170)
West Virginia (1)
Wisconsin (26)
311,563 Results for "deciphera pharmaceuticals llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
ONO Pharmaceutical, Co., Ltd., and Deciphera Pharmaceuticals, Inc. announced that on April 29, 2024, ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO.
April 30, 2024
·
10 min read
Deals
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.
April 29, 2024
·
10 min read
Deals
Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, “Ono”) today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc.
June 11, 2024
·
5 min read
Press Releases
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
February 17, 2025
·
10 min read
Genetown
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024 at 11:30 AM ET.
April 9, 2024
·
1 min read
Genetown
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - February 27, 2024
Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in fireside chats at the following investor conferences.
February 27, 2024
·
1 min read
Genetown
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 9:00 AM ET in New York, NY.
February 1, 2024
·
1 min read
Deals
Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint
Ono Pharmaceutical will pay $25.60 per share in an all-cash deal to buy Deciphera Pharmaceuticals for its potential blockbuster oncology drugs and U.S. sales infrastructure, the companies said Monday.
April 29, 2024
·
2 min read
·
Nick Paul Taylor
Business
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
February 6, 2024
·
13 min read
Genetown
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - November 7, 2023
Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in fireside chats at the following investor conferences.
November 7, 2023
·
1 min read
1 of 31,157
Next
